With the increasingly prominent impact of social media on the daily lives of today’s society, one would be surprised to find that only a small handful of pharmaceutical companies utilize these new media markets. A major reason for this stems from the FDA’s ambiguous regulation of Internet and social media, leaving regulatory professionals with the task of making unclear interpretations from Draft Guidance documents and Warning Letters. Nevertheless, a recent study has shown that between 2013 and 2016, some of the top Pharma companies have strengthened their Twitter followership by nearly 300% while also increasing the average number of tweets by 530%.¹ Clearly, pharmaceutical firms are beginning to embrace social media, and moving forward, it is important to recognize the regulatory challenges that come with the increased scope of these new platforms.